Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 80, Issue 1, 2012, Pages 194-202

  Branham, Michael Lee ^a   Moyo, Thomas ^a   Govender, Thirumala ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Ball milling; Drug delivery; Nanosizing; Saquinavir; Solid state characterization; Solubility enhancement

Indexed keywords

SAQUINAVIR;

ARTICLE; ATTENUATE TOTAL REFLECTANCE INFRARED SPECTROSCOPY; BUCCAL DRUG ADMINISTRATION; CARBON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FIELD EMISSIONS SCANNING ELECTRON MICROSCOPY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMOGRAVIMETRY; THERMOSTABILITY; X RAY DIFFRACTION;

ADMINISTRATION, BUCCAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DIFFERENTIAL THERMAL ANALYSIS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; NANOPORES; PARTICLE SIZE; POROSITY; POWDERS; SAQUINAVIR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 83955161728     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.08.005     Document Type: Article

References (47)

1. P. Sharma, and S. Garg Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs Adv. Drug Deliv. Rev. 62 2010 491 502
2. G.C. Williams, and P.J. Sinko Oral absorption of the HIV protease inhibitors: a current update Adv. Drug Deliv. Rev. 39 1999 211 238 (Pubitemid 29430237)
3. Invirase (saquinavir mesylate) capsules, prescribing information. In: Physicians' Desk Reference, Medical Economics Data Production Co., Montvale, NJ, 1998, pp. 247-2475.
4. H. Boudad, P. Legrand, G. Lebas, M. Cheron, D. Duchene, and G. Ponchel Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir Int. J. Pharm. 218 2001 113 124 (Pubitemid 32406162)
5. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, J.L. Little, M.G. Ramsey, K.M. Ruble, V.J. Wacher, and M.F. Wempe Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations Biomacromolecules 9 2008 305 313 (Pubitemid 351201613)
6. S.M. Pathak, P. Musmade, S. Dengle, A. Karthik, K. Bhat, and N. Udupa Enhanced oral absorption of saquinavir with methyl-beta-cyclodextrin - preparation and in vitro and in vivo evaluation Eur. J. Pharm. Sci. 41 2010 440 451
7. M.E. Fitzsimmons, and J.M. Collins Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism Drug Metab. Dispos. 25 1997 256 266 (Pubitemid 27086127)
8. V.A. Eagling, D.J. Back, and M.G. Barry Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir Br. J. Clin. Pharmacol. 44 1997 190 194 (Pubitemid 27327076)
9. J.C. Chaumeil Micronisation: a method of improving the bioavailability of poorly soluble drugs, methods find Exp. Clin. Pharmacol. 20 3 1998 211 215 (Pubitemid 28255411)
10. S. Agharkar, S. Lindenbaum, and T. Higuchi Enhancement of solubility of drug salts by hydrophilic counter-ions: properties of organic salts of an anti-malarial drug J. Pharm. Sci. 65 5 1976 747 749
11. K. Amin, R.-M. Dannenfelser, J. Zielinski, and B. Wang Lyophilization of polyethylene glycol mixtures J. Pharm. Sci. 93 9 2004 2244 2249 (Pubitemid 39129622)
12. V.P. Torchillin Micellar nanocarriers: pharmaceutical perspectives Pharm. Res. 24 2007 1 16
13. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery J. Pharm. Sci. 85 1996 1142 1169 (Pubitemid 26372882)
14. A.J. Humberstone, and W.N. Charman Lipid-based vehicles for the oral delivery of poorly soluble drugs Adv. Drug Deliv. Rev. 25 1997 103 128
15. A.T. Florence, E.G. Salole, and J.B. Stenlake The effect of particle size reduction on digoxin crystal properties J. Pharm. Pharmacol. 26 1974 479 480
16. K.C. Lee, and J.A. Hersey Crystal modification of methisazone by grinding J. Pharm. Pharmacol. 29 1979 249 250 (Pubitemid 8079057)
17. F. Muller, and R.F. Polke From the product and process requirements to the milling facility Powder Technol. 105 1999 2 13 (Pubitemid 29531588)
18. J. Hu, K.P. Johnston, and R.O. Williams III Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs Drug Dev. Ind. Pharm. 30 2004 233 245 (Pubitemid 38451748)
19. T. Takatsuka, T. Endo, J. Jianguo, K. Yuminoki, and N. Hashimoto Nanosizing of poorly water soluble compounds using rotation/revolution mixer Chem. Pharm. Bull. 57 2009 1061 1067
20. J.A.H. Junghanns, and R.H. Müller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
21. R.H. Muller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 1 2001 3 19 (Pubitemid 32209229)
22. C.M. Keck, and R.H. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization Eur. J. Pharm. Biopharm. 62 1 2006 3 16 (Pubitemid 41736019)
23. E. Merisko-Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, J.M. Shaw, S. Pugh, L. Polin, J. Jones, T. Corbett, E. Cooper, and G.G. Liversidge Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res. 13 1996 272 278 (Pubitemid 26074194)
24. T. Niwaa, Y. Nakanishib, and K. Danjoa One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen Eur. J. Pharm. Sci. 41 2010 78 85
25. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120 (Pubitemid 36184748)
26. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60 (Pubitemid 30326688)
27. A.M. Kaushal, P. Gupta, and A.K. Bansal Amorphous drug delivery systems: molecular aspects, design, and performance Crit. Rev. Ther. Drug Carrier Syst. 21 2004 133 193 (Pubitemid 41647581)
28. M.G. Fakes, B.J. Vakkalagadda, F. Qian, S. Desikan, R.B. Gandhi, C. Lai, A. Hsieh, M.K. Franchini, H. Toale, and J. Brown Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches Int. J. Pharm. 370 2009 167 174
29. S. Sethia, and E. Squillante Solid dispersions: revival with greater possibilities and applications in oral drug delivery Crit. Rev. Ther. Drug Carrier Syst. 20 2003 215 247 (Pubitemid 37237280)
30. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51 (Pubitemid 38195327)
31. A. Heinz, C.J. Strachan, F. Atassi, K.C. Gordon, and T. Rades Characterizing an amorphous system exhibiting trace crystallinity: a case study with saquinavir Crystal Growth Des. 8 2008 119 127
32. S. Azarmi, W. Roa, and R. Löbenberg Current perspectives in dissolution testing of conventional and novel dosage forms Int. J. Pharm. 328 2007 12 27
33. F.A. Mohamed, and H. Khedr Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate Drug Dev. Ind. Pharm. 29 2003 321 337 (Pubitemid 36528622)
34. S. Brunauer, P. Emmet, and E. Teller Adsorption of gases in multimolecular layers J. Am. Chem. Soc. 60 1938 309 319
35. E. Barret, L.G. Joyner, and P.P. Halenda The determination of pore volume and area distributions in porous substances. I. Computations from nitrogen isotherms J. Am. Chem. Soc. 73 1951 373 380
36. J.F. Bauer, W. Dziki, and J.E. Quick Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation J. Pharm. Sci. 88 1999 1222 1227 (Pubitemid 29526310)
37. G.A. Stephenson, E.G. Groleau, R.L. Kleeman, W. Xu, and D.R. Rigsbee Formation of isomorphic desolvates: creating a molecular vacuum J. Pharm. Sci. 87 1998 536 542 (Pubitemid 28225615)
38. H.G. Brittain Effects of mechanical processing on phase composition J. Pharm. Sci. 91 2002 1573 1580 (Pubitemid 34680220)
39. P.G. Royall, D.Q.M. Craig, and C. Doherty Characterization of moisture uptake effects on the glass transitional behavior of an amorphous drug using modulated temperature DSC Int. J. Pharm. 192 1999 39 46
40. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644 (Pubitemid 47285408)
41. D.S. Singare, S. Marella, K. Gowthamarajan, G.T. Kulkarni, R. Vooturi, and P.S. Rao Optimization of formulation and process variable of nanosuspension: an industrial perspective Int. J. Pharm. 402 2010 213 220
42. A.A. Date, and V.B. Patravale Current strategies for engineering drug nanoparticles Curr. Opin. Colloid Interface Sci. 9 2004 222 235 (Pubitemid 39586699)
43. Y. Kuo, and H. Chen Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles Int. J. Pharm. 365 2009 206 213
44. S. Desprez, and M. Descamps Transformation of glassy indomethacin by ball-milling J. Non-Cryst. Solids 352 2006 4480 4485
45. G. Bruni, V. Berbenni, F. Sartor, C. Milanese, A. Girella, D. Franchi, and A. Marini Quantification methods of amorphous/crystalline fractions in high-energy ball milled pharmaceutical products J. Therm. Anal. Calorim. 102 2010 297 303
46. B. Hancock, and M. Parks What is the solubility advantage for amorphous pharmaceuticals Pharm. Res. 17 2000 397 404 (Pubitemid 30395293)
47. E. Biazar, A. Beitollahi, S.M. Rezayat, T. Forati, A. Asefnejad, M. Rahimi, R. Zeinali, M. Ardesir, F. Hatamjafari, A. Sahebalzamani, and M. Heidari Effect of the mechanical activation on size reduction of crystalline acetaminophen drug particles Int. J. Nanomed. 4 2009 283 287